Alpheus Medical Opens Enrollment in New Clinical Trial for Butterfly Glioblastoma
The study will evaluate PoMA™ therapy, Alpheus' drug-led, tumor-selective treatment approach, in patients with butterfly glioblastoma, a particularly aggressive form of GBM involving both cerebral hemispheres. The trial design requires PoMA therapy prior to standard chemoradiation...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Résiliable à tout moment · 99 $ CA/mois


